Original Report| Volume 17, ISSUE 6, P739-744, June 2016

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain


      • Cannabis use was associated with 64% lower opioid use in patients with chronic pain.
      • Cannabis use was associated with better quality of life in patients with chronic pain.
      • Cannabis use was associated with fewer medication side effects and medications used.


      Opioids are commonly used to treat patients with chronic pain (CP), though there is little evidence that they are effective for long term CP treatment. Previous studies reported strong associations between passage of medical cannabis laws and decrease in opioid overdose statewide. Our aim was to examine whether using medical cannabis for CP changed individual patterns of opioid use. Using an online questionnaire, we conducted a cross-sectional retrospective survey of 244 medical cannabis patients with CP who patronized a medical cannabis dispensary in Michigan between November 2013 and February 2015. Data collected included demographic information, changes in opioid use, quality of life, medication classes used, and medication side effects before and after initiation of cannabis usage. Among study participants, medical cannabis use was associated with a 64% decrease in opioid use (n = 118), decreased number and side effects of medications, and an improved quality of life (45%). This study suggests that many CP patients are essentially substituting medical cannabis for opioids and other medications for CP treatment, and finding the benefit and side effect profile of cannabis to be greater than these other classes of medications. More research is needed to validate this finding.


      This article suggests that using medical cannabis for CP treatment may benefit some CP patients. The reported improvement in quality of life, better side effect profile, and decreased opioid use should be confirmed by rigorous, longitudinal studies that also assess how CP patients use medical cannabis for pain management.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Arnold L.M.
        • Clauw D.J.
        • Dunegan L.J.
        • Turk D.C.
        A framework for fibromyalgia management for primary care providers.
        Mayo Clin Proc. 2012; 87: 488-496
        • Bachhuber M.A.
        • Salone B.
        • Cunningham C.O.
        • Barry C.L.
        Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010.
        JAMA Intern Med. 2014; 19104: 1-6
        • Brummett C.
        • Janda A.
        • Schueller C.
        • Tsodikov A.
        • Morris M.
        • Williams D.
        • Clauw D.
        Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty.
        Anesthesiology. 2013; 119: 1434-1443
        • Clauw D.J.
        Fibromyalgia: A clinical review.
        JAMA. 2014; 311: 1547-1555
        • Degenhardt L.
        • Lintzeris N.
        • Campbell G.
        • Bruno R.
        • Cohen M.
        • Farrell M.
        • Hall W.D.
        Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study.
        Drug Alcohol Depend. 2015; 147: 144-150
        • Farrell M.
        • Buchbinder R.
        • Hall W.
        Should doctors prescribe cannabinoids?.
        BMJ. 2014; 348: g2737
        • Hazekamp A.
        • Heerdink E.R.
        The prevalence and incidence of medicinal cannabis on prescription in the Netherlands.
        Eur J Clin Pharmacol. 2013; 69: 1575-1580
        • Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education
        Relieving pain in America: A blueprint for transforming prevention, care, education, and research.
        National Academies Press (US), Washington, DC2011
        • Janda A.M.
        • As-Sanie S.
        • Rajala B.
        • Tsodikov A.
        • Moser S.E.
        • Clauw D.J.
        • Brummett C.M.
        Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy.
        Anesthesiology. 2015; 122: 1103-1111
        • Jones C.M.
        • Mack K.A.
        • Paulozzi L.J.
        Pharmaceutical overdose deaths, United States, 2010.
        JAMA. 2013; 309: 657-659
      1. LARA. Department of Licensing and Regulatory Affairs: MAPS Statistics. Available at:,4601,7-154-72600_72603_55478_55484---,00.html

        • Leung L.
        Cannabis and its derivatives: Review of medical use.
        J Am Board Fam Med. 2011; 24: 452-462
        • Lynch M.E.
        • Campbell F.
        Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
        Br J Clin Pharmacol. 2011; 72: 735-744
        • Phillips K.
        • Clauw D.J.
        Central pain mechanisms in the rheumatic diseases: Future directions.
        Arthritis Rheum. 2013; 65: 291-302
        • Whiting P.F.
        • Wolff R.F.
        • Deshpande S.
        • Di Nisio M.
        • Duffy S.
        • Hernandez A.V.
        • Keurentjes J.C.
        • Lang S.
        • Misso K.
        • Ryder S.
        • Schmidlkofer S.
        • Westwood M.
        • Kleijnen J.
        Cannabinoids for medical use.
        JAMA. 2015; 313: 2456-2473
        • Wolfe F.
        • Clauw D.J.
        • Fitzcharles M.A.
        • Goldenberg D.L.
        • Häuser W.
        • Katz R.S.
        • Mease P.
        • Russell A.S.
        • Russell I.J.
        • Winfield J.B.
        Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia.
        J Rheumatol. 2011; 38: 1113-1122
      2. Advisory Committee on Pain and Symptom Management: 2014: The “state” of pain in Michigan. Available at: